GSKH vs. IDNA

Last updated Jun 6, 2026

GSKH (GSK plc ADRhedged ETF) and IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) are both Health & Biotech Equities funds - GSKH tracks the GSK plc Local Shares Total Return while IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index. Both are passively managed. Over the past year, GSKH returned 30.78% vs 42.29% for IDNA. At a 0.40 correlation, their price movements are largely independent. GSKH charges 0.19%/yr vs 0.47%/yr for IDNA.

Performance

GSKH vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GSK plc ADRhedged ETF (GSKH) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GSKH achieves a 7.84% return, which is significantly lower than IDNA's 11.26% return.

GSKH

• 1D: 1.34%
• 1M: 4.57%
• YTD: 7.84%
• 6M: 8.19%
• 1Y: 30.78%
• 3Y*: —
• 5Y*: —
• 10Y*: —

IDNA

• 1D: -2.74%
• 1M: -4.27%
• YTD: 11.26%
• 6M: 8.76%
• 1Y: 42.29%
• 3Y*: 6.76%
• 5Y*: -8.26%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

GSKH vs. IDNA - Yearly Performance Comparison

	2026 (YTD)	2025
GSKH GSK plc ADRhedged ETF	7.84%	37.05%
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	11.26%	12.30%

Correlation

The correlation between GSKH and IDNA is 0.36, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.36
Correlation (All Time) Calculated using the full available price history since Jan 8, 2025	0.40

GSKH vs. IDNA - Sectors Allocation Comparison

Sectors	GSKH	IDNA
Healthcare	100.0%	97.8%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	-
Industrials	-	0.4%
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

GSKH vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GSKH

GSKH Risk / Return Rank: 36
GSKH Sharpe Ratio Rank: 36
GSKH Sortino Ratio Rank: 39
GSKH Omega Ratio Rank: 38
GSKH Calmar Ratio Rank: 37
GSKH Martin Ratio Rank: 30

IDNA

IDNA Risk / Return Rank: 59
IDNA Sharpe Ratio Rank: 52
IDNA Sortino Ratio Rank: 53
IDNA Omega Ratio Rank: 46
IDNA Calmar Ratio Rank: 80
IDNA Martin Ratio Rank: 64

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GSKH vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for GSK plc ADRhedged ETF (GSKH) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GSKH	IDNA	Difference
Sharpe ratio: Return per unit of total volatility	1.18	1.71	-0.53
Sortino ratio: Return per unit of downside risk	1.82	2.47	-0.65
Omega ratio: Gain probability vs. loss probability	1.23	1.28	-0.05
Calmar ratio: Return relative to maximum drawdown	1.67	3.98	-2.32
Martin ratio: Return relative to average drawdown	4.06	11.26	-7.21
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GSKH vs. IDNA - Sharpe Ratio Comparison

The current GSKH Sharpe Ratio is 1.18, which is lower than the IDNA Sharpe Ratio of 1.71. The chart below compares the historical Sharpe Ratios of GSKH and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	GSKH	IDNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.18	1.71	-0.53
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.29	—
Sharpe Ratio (All Time) Calculated using the full available price history	1.19	0.10	+1.08

Drawdowns

GSKH vs. IDNA - Drawdown Comparison

The maximum GSKH drawdown since its inception was -18.54%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for GSKH and IDNA.

Drawdown Indicators

	GSKH	IDNA	Difference
Max Drawdown Largest peak-to-trough decline	-18.54%	-68.26%	+49.72%
Max Drawdown (1Y) Largest decline over 1 year	-18.54%	-10.66%	-7.88%
Max Drawdown (3Y) Largest decline over 3 years	—	-29.73%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-68.26%	—
Current Drawdown Current decline from peak	-13.28%	-45.14%	+31.86%
Average Drawdown Average peak-to-trough decline	-5.65%	-36.25%	+30.60%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.61%	3.76%	+3.85%

Volatility

GSKH vs. IDNA - Volatility Comparison

The current volatility for GSK plc ADRhedged ETF (GSKH) is 6.33%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 7.93%. This indicates that GSKH experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GSKH	IDNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.33%	7.93%	-1.60%
Volatility (6M) Calculated over the trailing 6-month period	18.35%	18.20%	+0.15%
Volatility (1Y) Calculated over the trailing 1-year period	26.30%	24.88%	+1.42%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	27.08%	28.47%	-1.39%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.08%	29.56%	-2.48%

GSKH vs. IDNA - Expense Ratio Comparison

GSKH has a 0.19% expense ratio, which is lower than IDNA's 0.47% expense ratio.

Dividends

GSKH vs. IDNA - Dividend Comparison

GSKH's dividend yield for the trailing twelve months is around 1.57%, more than IDNA's 1.06% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019
GSKH GSK plc ADRhedged ETF	1.57%	1.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	1.06%	1.18%	0.98%	1.04%	0.54%	0.70%	0.26%	0.80%

Frequently Asked Questions

Can I hold both GSKH and IDNA in my portfolio?

GSKH and IDNA have a correlation of 0.36, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, GSKH or IDNA?

IDNA has higher volatility (7.93%) compared to GSKH (6.33%). In terms of maximum drawdown, GSKH dropped -18.54% vs IDNA's -68.26%.

Which ETF is better, GSKH or IDNA?

On 1-year performance, IDNA leads with 42.29% vs 30.78% for GSKH. On fees, GSKH is cheaper at 0.19% per year. On volatility, GSKH has been the lower-risk option at 6.33%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, GSKH or IDNA?

Over the 1-year period, IDNA has performed better with a 42.29% return vs 30.78%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, GSKH or IDNA?

GSKH is cheaper with a 0.19% expense ratio, compared with 0.47% for IDNA.

Which ETF pays a higher dividend yield, GSKH or IDNA?

GSKH has the higher dividend yield at 1.57%, compared with 1.06% for IDNA.

What is the main difference between GSKH and IDNA?

GSKH tracks GSK plc Local Shares Total Return, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. They also come from different issuers: ADRhedged and iShares. Their fees differ too: 0.19% for GSKH and 0.47% for IDNA.

Which has better risk-adjusted returns?

IDNA currently has the higher Sharpe Ratio (1.71 vs 1.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.